Reaction
Retinal Oedema reporting signals
As of the last recalculation, Retinal Oedema appears in 1,860 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 195.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 371 | 195.1 | 197.9 |
| Aflibercept | 266 | 111.2 | 112.1 |
| Faricimab | 30 | 42.1 | 42.2 |
| Encorafenib | 26 | 29.8 | 29.9 |
| Cefuroxime | 22 | 21.8 | 21.8 |
| Bevacizumab | 202 | 20.4 | 20.4 |
| Prednisolone Acetate | 13 | 14.2 | 14.2 |
| Ganciclovir Sodium | 12 | 12.8 | 12.8 |
| Brinzolamide | 9 | 11.6 | 11.7 |
| Dorzolamide Hydrochloride And Timolol Maleate | 8 | 11.4 | 11.4 |
| Moxifloxacin Hydrochloride | 20 | 11.1 | 11.2 |
| Ganciclovir | 9 | 9.9 | 9.9 |
| Fingolimod Hcl | 68 | 9.1 | 9.1 |
| Timolol | 7 | 6.5 | 6.5 |
| Siponimod | 5 | 6.3 | 6.3 |
| Brimonidine Tartrate | 9 | 5.7 | 5.7 |
| Vemurafenib | 6 | 5.6 | 5.6 |
| Ozanimod Hydrochloride | 4 | 5.4 | 5.4 |
| Cenegermin-Bkbj | 3 | 2.8 | 2.8 |